title: [Mantle cell lymphoma, response to treatment and prognosis in 45 patients].
abstract: OBJECTIVE
  Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder, with frequent relapses and a poor prognosis. This study analyzes response to treatment and prognosis in a series of MCL patients.
  
  
  METHODS
  Retrospective study of MCL patients diagnosed in a single institution between 1996 and 2013. The cohort was divided according to the treatment received.
  
  
  RESULTS
  Forty-five patients were included (32 male) with a median age of 66 years old. Twenty-one received intensive chemotherapy or chemoimmunotherapy (based on high-dose cytarabine), 13 semi-intensive (without high-dose cytarabine), 8 not intensive and 3 did not require treatment. Overall response rate was 85% in the intensive and 77% in the semi-intensive treatment groups. In multivariate analysis, intensive treatment was correlated with a longer progression-free survival (hazard ratio 9.8 [95% CI 2.7-35.5], P=.001) and overall survival (4.5 [1.2-17.8], P=.03).
  
  
  CONCLUSIONS
  In this retrospective series of MCL patients, intensive treatment was correlated with better outcomes than the other treatment modalities.
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España. Electronic address: mc.sorigue@zoho.com.
authors.forename: Marc
authors.initials: M
authors.lastname: Sorigue
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors.forename: Juan-Manuel
authors.initials: JM
authors.lastname: Sancho
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors.forename: Olga
authors.initials: O
authors.lastname: García
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors.forename: Jordi
authors.initials: J
authors.lastname: Vila
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors.forename: Miriam
authors.initials: M
authors.lastname: Moreno
authors.affiliation: Servicio de Hematología Clínica, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine
keywords: Dosis altas de citarabina; High-dose cytarabine; Linfoma de células del manto; Mantle cell lymphoma; Prognosis; Pronóstico